NMN

Nicotinamide Mononucleotide
Also known as: NMN, Beta-NMN
Supplement

Content by: OpenSupplement Editorial Team  |  Medical review: pending  |  Last updated: April 13, 2026

Evidence ★★★☆☆3/5
Best for
CognitionHeart
Typical dose250-500 mg/day
SafetyNo significant concerns
Onset4–8 weeks
Cost$50-100/mo
References3 studies cited

TL;DR

  • NAD+ precursor molecule, alternative to nicotinamide riboside

  • University of Washington trial showed improved insulin sensitivity

  • Converts to NAD+ through different pathway than NR

  • Generally well-tolerated but limited long-term safety data

  • Monthly cost: $50-100 for quality brands

  • Best for: metabolic health in prediabetes, experimental longevity protocols

What it is

NMN (nicotinamide mononucleotide) is a precursor to NAD+, the cellular energy molecule that declines with aging. Unlike nicotinamide riboside (NR), which enters cells and converts to NMN before becoming NAD+, NMN theoretically skips the middle step — though recent research suggests it may actually be broken down to NR before cellular uptake anyway.

The supplement gained mainstream attention through Harvard researcher David Sinclair's advocacy and personal use. NMN follows a different biochemical pathway than NR to boost NAD+ levels, leading to ongoing debates about which approach is superior. Recent human trials have begun to provide actual data rather than just theoretical arguments.

What the research says

Metabolic syndromeRelevance: Low
Evidence
2.5/5
Onset speed
2/5
Typical dose: 250-500 mg/day

The University of Washington trial provides the strongest NMN evidence [1]. Prediabetic women taking 250mg daily for 10 weeks showed improved muscle insulin sensitivity compared to placebo. This is significant because muscle insulin resistance is central to type 2 diabetes development.

However, this is still just one study with a specific population. The Japanese trial [2] in healthy men showed increased NAD+ levels but no clear metabolic improvements. Mouse studies [3] are more dramatic but don't always translate to humans.

For established metabolic syndrome, proven interventions like metformin, weight loss, and exercise have much stronger evidence. NMN might be worth considering for early insulin resistance, but it's still experimental.

Cognitive declineRelevance: Low
Evidence
2/5
Onset speed
2/5
Typical dose: 250-500 mg/day

Human cognitive data is extremely limited for NMN compared to other NAD+ precursors. The University of Washington study [1] measured metabolic outcomes but didn't assess cognitive function. A small Japanese study [2] looked at some biomarkers but found no clear cognitive benefits.

Most cognitive claims rest on animal studies [3] showing improved brain NAD+ levels and neuronal function in aged mice. While promising mechanistically, the translation to human cognitive enhancement remains unproven.

If you're interested in NAD+ precursors for cognitive health, nicotinamide riboside has stronger human data at this point. NMN may prove equally effective, but the evidence simply isn't there yet.

Heart diseaseRelevance: Low
Evidence
2/5
Onset speed
2/5
Typical dose: 250-500 mg/day

Cardiovascular data for NMN is essentially non-existent in humans. The theoretical rationale is the same as other NAD+ precursors — declining NAD+ with aging may contribute to cardiovascular aging, and restoration could help.

Mouse studies are encouraging [3], showing improved arterial function and reduced age-related cardiovascular decline. But rodent cardiovascular physiology doesn't always match human responses.

For heart health, stick with proven interventions — exercise, Mediterranean diet, blood pressure control. NMN remains speculative for cardiovascular benefits.

DISCLAIMER: The information on this page is for educational purposes only and has not been evaluated by the Food and Drug Administration. This content is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before using any dietary supplement, especially if you are pregnant, nursing, taking medication, or have a medical condition.

This page may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. Learn more.

NMN on Amazon

$50-100/mo (estimated)
See on Amazon

Safety

NMN appears well-tolerated in the limited human trials completed. The University of Washington study [1] and Japanese trial [2] reported no significant adverse effects at doses up to 250-300mg daily. Some users report mild nausea if taken on an empty stomach.

The main concern is limited long-term safety data — we simply don't know what happens with years of use. The FDA's fluctuating regulatory stance reflects uncertainty about both efficacy and safety. As with any experimental supplement, conservative dosing and medical supervision make sense.

Interactions

• No documented drug interactions in published trials • Theoretical concerns about boosting NAD+ in cancer patients (NAD+ supports cell division) • Blood sugar medications — monitor glucose if diabetic, though NMN may improve insulin sensitivity • No significant interactions reported with common medications

Dosing

For metabolic benefits: 250mg daily, based on the University of Washington trial [1]. Take with food to minimize nausea.

Experimental longevity protocols: 250-500mg daily, though higher doses lack human validation. Some advocates take up to 1000mg, but this exceeds studied amounts.

Timing: Morning dosing may align better with circadian NAD+ rhythms. Sublingual forms claim better absorption but lack comparative studies. Powder forms are typically more cost-effective than capsules.

Cost

Quality NMN ranges from $50-100 monthly for 250-500mg daily. Powder forms run $40-70 monthly, while capsules cost $60-100. The price reflects complex manufacturing and uncertain regulatory status driving up costs. Generic versions are emerging but quality varies significantly — third-party testing is essential given the lack of FDA oversight.

The bottom line

NMN shows early promise for metabolic health, with one solid human trial supporting improved insulin sensitivity. However, the evidence base is much thinner than established interventions, and long-term safety remains unknown. Consider it experimental — potentially worthwhile for early metabolic dysfunction or as part of a comprehensive longevity protocol, but not as a primary intervention. If you're choosing between NAD+ precursors, nicotinamide riboside currently has stronger human data, though NMN may prove equally effective as more trials emerge.

References

  1. RCTMetabolic syndromePubMed
  2. RCTMetabolic syndromeCognitive declinePubMed
  3. MechanisticMetabolic syndromeHeart diseaseCognitive declinePubMed

Sources for this page include published meta-analyses, systematic reviews, and NIH dietary supplement fact sheets. All claims reflect the evidence as of early 2026.

This is not medical advice. Consult your healthcare provider before starting any supplement, especially if you take medications.